Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies
This is a phase l study to examine Absorption, Distribution, Metabolism and Excretion of TKI258. There are 2 cohorts. Cohort 1 (4 patients) will receive single radio-labeled 500mg dose of TKI258 followed after 15 days by daily dosing of 400mg TKI258. Cohort 2 (9 patients) will receive 400mg TKI258.
Advanced Solid Malignancies
DRUG: TKI258
Cohort1: Find out about the routes and rates of excretion of TKI258 and its metabolites, Day 15|Cohort 2: Safety and Tolerability of TKI258, Time to patient withdrawal due to disease progression or tolerability issues
Cohort 1: Safety and tolerability of TKI258, Time to patient withdrawal due to disease progression or tolerability issues|Cohort 1: Preliminary anti-tumor activity of TKI258, Time to tumor progression|Preliminary Anti-tumor activity of TKI258, Time to tumor progression
This is a phase l study to examine Absorption, Distribution, Metabolism and Excretion of TKI258. There are 2 cohorts. Cohort 1 (4 patients) will receive single radio-labeled 500mg dose of TKI258 followed after 15 days by daily dosing of 400mg TKI258. Cohort 2 (9 patients) will receive 400mg TKI258.